Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective Multicenter, Double-Masked, Randomized, Parallel-Group, Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI (Axitinib Implant) for Intravitreal Use in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)

Next Previous
X
Search
Trial Profile

A Prospective Multicenter, Double-Masked, Randomized, Parallel-Group, Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI (Axitinib Implant) for Intravitreal Use in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axitinib (Primary) ; Aflibercept
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions
  • Sponsors Ocular Therapeutix

    • Most Recent Events

    • 05 Sep 2024 According to an Ocular Therapeutix media release, data from the study will be presented at retina meetings being held in Portugal and Spain in September 2024.
    • 25 Jan 2024 Status changed from active, no longer recruiting to completed.
    • 03 Oct 2023 According to an Ocular Therapeutix media release, the pivotal trial was initiated based on the previously announced positive 12-month top-line data from the Companys 21-subject U.S.-based Phase 1 trial of OTX-TKI for the treatment of wet AMD

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top